Mary Beckerle - Johnson Johnson Director

JNJ Stock  EUR 140.06  0.94  0.67%   

Director

Dr. Mary C. Beckerle, Ph.D., is an Independent Director of the Company. She has served as CEO of Huntsman Cancer Institute at the University of Utah since 2006. She is the associate vice president for cancer affairs and a distinguished professor of biology and oncological sciences at the University of Utah. Dr. Beckerle joined the faculty of the University of Utah in 1986 and currently holds the Jon M. Huntsman Presidential Endowed Chair. Dr. Beckerle has served on the National Institute of Health Advisory Committee to the Director, on the Board of Directors of the American Association for Cancer Research, as president of the American Society for Cell Biology, and as the Chair of the American Cancer Society Council for Extramural Grants. She currently serves on a number of scientific advisory boards, including the Medical Advisory Board of the Howard Hughes Medical Institute, and the Scientific Advisory Boards of the National Center for Biological Sciences at the Tata Institute of Fundamental Research in India, the Mechanobiology Institute in Singapore, and the Dana FarberHarvard Cancer Center. Dr. Beckerle held a Guggenheim Fellowship at the Curie Institute in Paris, received the Utah Governors Medal for Science and Technology in 2001, the Sword of Hope Award from the American Cancer Society in 2004 and is an elected Fellow of the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Beckerle was also named a National Association of Corporationrationrate Directors Governance Fellow in 2012. since 2015.
Age 63
Tenure 9 years
Phone732 524 0400
Webhttps://www.jnj.com

Johnson Johnson Management Efficiency

The company has return on total asset (ROA) of 0.0871 % which means that it generated a profit of $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2379 %, meaning that it generated $0.2379 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 26.89 B in total debt with debt to equity ratio (D/E) of 0.48, which is about average as compared to similar companies. Johnson Johnson has a current ratio of 1.36, which is within standard range for the sector. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

York DyckerhoffAir New Zealand
51
Michael GlennPentair plc
62
Oliviero BregaAir New Zealand
72
Theodore HarrisPentair plc
53
Michele BuzziAir New Zealand
56
Michael SpeetzenPentair plc
48
Bruns GraysonRibbon Communications
71
Paolo BurlandoAir New Zealand
56
Linda GilliAir New Zealand
66
Antonella MusyAir New Zealand
51
Maurizio SellaAir New Zealand
77
Jacques EsculierPentair plc
58
Marco WeigmannAir New Zealand
75
Pietro BuzziAir New Zealand
58
Ronald MerrimanPentair plc
73
Gianfelice RoccaAir New Zealand
71
Billie WilliamsonPentair plc
65
Luca FabbroAir New Zealand
52
David JonesPentair plc
60
Elsa ForneroAir New Zealand
71
Glynis BryanPentair plc
59
Johnson Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. Johnson Johnson was founded in 1886 and is based in New Brunswick, New Jersey. JOHNSON JOHNSON operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 136000 people. Johnson Johnson (JNJ) is traded on Frankfurt Exchange in Germany and employs 152,700 people.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dirk Brinckman, Chief Officer
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman of the Board, CEO
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, Vice President General Counsel
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Ex CFO
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Director
Sandra Peterson, Group Worldwide Chairman
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Robert Decker, Controller Officer
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
James Swanson, Ex Officer
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Vice President - Investor Relations
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Jessica Moore, VP Relations
Ian Davis, Independent Director
Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Elizabeth Forminard, Exec Counsel
Dominic Caruso, CFO, Vice President - Finance
Peter Fasolo, Vice President - Global Human Resources
Susan Lindquist, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Johnson Johnson in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Johnson Johnson's short interest history, or implied volatility extrapolated from Johnson Johnson options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Johnson Stock please use our How to Invest in Johnson Johnson guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.